Prof. Dr. Florian Eyer
Academic Career and Research Areas
The field of research of Professor Eyer (b. 1971) is experimental and clinical toxicology. The aim of his research is to gain a better understanding of toxicokinetic and toxicodynamic processes and reappraise them using experimental and clinical models that reflect clinical conditions as closely as possible. Key aspects of his research are primary and secondary methods of poison elimination, addiction medicine and toxicological intensive care treatment.
After completing his undergraduate and doctoral studies (2000) at LMU Munich, Professor Eyer took up a position at TUM where he worked with Professor M. Classen in the field of gastroenterology and as of 2001 with Professor T. Zilker in the field of clinical toxicology. In 2007 he acquired his German medical board certification in internal medicine. He acquired an additional certification in internal intensive care medicine in 2009 and in addiction medicine in 2010. Professor Eyer obtained his postdoctoral teaching qualification (habilitation) in 2010 and became senior physician in the Department of Toxicology. His clinical specialities are critical care toxicology and addiction medicine. He was appointed professor in 2012.
Key Publications (all publications)
Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J: "Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis". Am J Gastroenterol. 2018; 113(10): 1475-83.Abstract
Schrettl V, Felgenhauer N, Rabe C, Fernando M, Eyer F: "L-Arginine in the treatment of valproate overdose - five clinical cases". Clin Toxicol (Phila). 2017; 55(4): 260-266.Abstract
Fischer J, Eberlein B, Hilger C, Eyer F, Eyerich S, Ollert M, Biedermann T: "Alpha-gal is a possible target of IgE-mediated reactivity to antivenom". Allergy. 2017; 72(5): 764-771.Abstract
Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Datz C, Schmelz R, Brückner S, Zeissig S, Stephan AM, Wodarz N, Devière J, Clumeck N, Sarrazin C, Lammert F, Gustot T, Deltenre P, Völzke H, Lerch MM, Mayerle J, Eyer F, Schafmayer C, Cichon S, Nöthen MM, Nothnagel M, Ellinghaus D, Huse K, Franke A, Zopf S, Hellerbrand C, Moreno C, Franchimont D, Morgan MY, Hampe J: "A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis". Nat Genet. 2015; 47(12): 1443-8.Abstract
Eyer F, Steimer W, Nitzsche T, Jung N, Neuberger H, Müller C, Schlapschy M, Zilker T, Skerra A: “Intravenous application of an Anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats”. Toxicol Appl Pharmacol. 2012; 263(3): 352-359.Abstract